´Ù½Ã ÇÁ·ÎÀÌÆ®; ³» ¸¶À½ÀÇ »óó¸¦ ÀдÙ.
- ÀúÀÚ(±Û)À¯¹üÈñ
- ÃâÆÇ»ç´õ½£ ÃâÆÇ»ç
- ¹ßÇàÀÏ2016³â 6¿ù 30ÀÏ
¼Ä¹°ÇÐÀû Ä¡·á¿Í Á¤½ÅÄ¡·á ¸ðµÎ¸¦ ¾Æ¿ì¸£´Â Á¤½ÅÀÇÇÐ Àü¹®°¡
¼¿ïÀǴ븦 Á¹¾÷ÇÏ°í ¼¿ï´ëÇб³º´¿ø¿¡¼ Àü°øÀÇ ¼ö·Ã ÈÄ Á¤½Å°ú Àü¹®ÀǸ¦ ÃëµæÇÏ¿´°í 1994³âºÎÅÍ 2014³â±îÁö ¼º±Õ°ü´ëÇб³ »ï¼º¼¿ïº´¿ø¿¡¼ 20³â°£ Á¤½Å°Ç°ÀÇÇаú ±³¼ö, °úÀå ¹× ÁÖÀÓ±³¼ö±îÁö ¿ªÀÓÇÏ¿´À½. ¹Ì±¹ University of California, San Diego ´ëÇп¡¼ 1997³âºÎÅÍ 1999³â±îÁö research fellow·Î ±Ù¹«ÇÏ¿´°í, ¹Ì±¹ San Diego Á¤½ÅºÐ¼®¿¬±¸¼Ò¿¡¼ Á¤½ÅÄ¡·á Àü¹®°¡ °úÁ¤µµ ÇÔ²² ¼ö·áÇÏ¿´À½. ÁÖ·Î °øÈ²Àå¾Ö, ºÒ¾ÈÀå¾Ö, ¿ì¿ïÁõ, ¼ö¸éÀå¾Ö, Á¤½ÅºÐ¼® ºÐ¾ß¸¦ Àü°øÇÏ¿´°í »ï¼º¼¿ïº´¿ø ±³¼ö·Î ÀçÁ÷ÇÏ¸é¼ ±¹³»¿Ü À¯¸í ÇмúÁö¿¡ 120Æí ÀÌ»óÀÇ ³í¹®À» ¹ßÇ¥ÇÏ¿´°í ´Ù¼öÀÇ Çмú»óÀ» ¼ö»óÇϱ⵵ ÇÔ. ¶ÇÇÑ Çѱ¹Á¤½ÅºÐ¼®ÇÐȸ ȸÀå, Çѱ¹Á¤½Å½ÅüÀÇÇÐȸ ȸÀå, ´ëÇѼö¸éÀÇÇÐȸ ÀÌ»çÀå, ´ëÇѺҾÈÀÇÇÐȸ °øÈ²-¹üºÒ¾ÈÀå¾Ö ¿¬±¸È¸ ÃÊ´ëȸÀå µîÀ» ¿ªÀÓÇÏ¸é¼ È°¹ßÇÑ ÇÐȸȰµ¿À» À̾. 2014³âºÎÅÍ Áö±Ý±îÁö À¯¹üÈñ Á¤½Å°Ç°ÀÇÇаú ¿øÀåÀ¸·Î ±Ù¹«ÇÏ¸é¼ ÀÓ»óÁø·á¿¡ Àü³äÇϰí ÀÖÀ½
| Á¦ ¸ñ | ±×¸²ÀÚ ¾ÆÀ̰¡ ¿ï°í ÀÖ´Ù. | ||
|---|---|---|---|
| ÃâÆÇ»ç | »ý°¢ ¼ÓÀÇ Áý | ¹ßÇàÀÏ | 2018³â |
| Á¦ ¸ñ | ºÒ¾ÈÀå¾Ö ¡¤ ½Å°æÁ¤½ÅÀÇÇÐ 2ÆÇ | ||
|---|---|---|---|
| ÃâÆÇ»ç | Áß¾Ó¹®È»ç | ¹ßÇàÀÏ | 2005³â |
| Á¦ ¸ñ | Psychiatric and Psychosocial Complications in Chronic Dialysis. In : Complications of Dialysis. edited by Mehta R and Ramiere N. | ||
|---|---|---|---|
| ÃâÆÇ»ç | New York, Marcel Dekker, Inc. | ¹ßÇàÀÏ | 2000³â |
| Á¦ ¸ñ | Changes in cerebral cortex and limbic brain functions after short-term paroxetine treatment in panic disorder: An [18F]FDG-PET pilot study. | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2010³â | ¹ßÇ¥Áö | Psychiatry Investigation |
| Á¦ ¸ñ | Sympathetic nervous function and the effect of the catechol-O-methyltransferase Val158Met polymorphism in patients with panic disorder. | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2010³â | ¹ßÇ¥Áö | J of Affective Disorder |
| Á¦ ¸ñ | Platelet serotonin transporter function after short-term paroxetine treatment in patients with panic disorder. | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2010³â | ¹ßÇ¥Áö | Psyciatry Research |
| Á¦ ¸ñ | Mirtazapine versus venlafaxine for the treatment of somatic symptoms associated with major depressive disorder: A randomized, open-labeled trial. | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2009³â | ¹ßÇ¥Áö | Psyciatry Research |
| Á¦ ¸ñ | ¥â-adrenoceptor affinity as a biological predictor of treatment response to paroxetine in patients with acute panic disorder. | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2008³â | ¹ßÇ¥Áö | J of Affective Disorder |
| Á¦ ¸ñ | Mood states, sympathetic activity and in vivo ¥â-adrenergic receptor function in a normal population. | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2008³â | ¹ßÇ¥Áö | Depression & Anxiety |
| Á¦ ¸ñ | Increased cholesterol levels after paroxetine treatment in patients with panic disorder | ||
|---|---|---|---|
| ¹ßÇ¥³âµµ | 2005³â | ¹ßÇ¥Áö | J Clin Psychopharmacol |
°øÈ²Àå¾Ö¿¡ ´ëÇÑ »ý¹°ÇÐÀû ¿¬±¸¿¡ °¡Àå Å« °ü½ÉÀ» µÎ¾î¿Ô°í 2002³âµµ¿¡ Á¤½ÅÀÇÇÐ ºÐ¾ß¿¡¼ ¼¼°èÀûÀÎ ÇмúÁö·Î ÀÎÁ¤¹Þ´Â American Journal of Psychiatry¿¡ Catechol-O-methyltransferase genetic polymorphism in panic disorder¶ó´Â ³í¹®À» ¹ßÇ¥ÇÏ¿© °øÈ²Àå¾Ö¿¡¼ À¯ÀüÀû ¹ßº´ ¿äÀο¡ ´ëÇÑ ÁÖ¿ä °¡¼³À» óÀ½À¸·Î ¹ßÇ¥ÇÏ¿´½À´Ï´Ù. ±×¸®°í ÀÌ ³í¹®À¸·Î 2004³âµµ¿¡ ´ëÇѽŰæÁ¤½ÅÀÇÇÐȸ GSK Çмú»ó°ú Çѱ¹°úÇбâ¼úÃÑ¿¬ÇÕȸ¿¡¼ ¿ì¼ö¿¬±¸ÀÚ¿¡°Ô ¼ö¿©ÇÏ´Â Çмú»óÀ» ¼ö»óÇϱ⵵ ÇÏ¿´½À´Ï´Ù.
ȯÀÚ°¡ ÀÚÄ© ³¸¼³°í ±äÀåÇÒ ¼öµµ ÀÖ´Â Á¤½Å°ú Áø·á¿¡ °¡´ÉÇÑ Æí¾ÈÇÏ°Ô ÀûÀÀÇÒ ¼ö ÀÖµµ·Ï µ½°í µû¶ó¼ ȯÀÚÀÇ ¾ê±â¸¦ ÃÖ´ëÇÑ °æÃ»ÇÏ·Á°í ³ë·ÂÇÕ´Ï´Ù. ±×¸®°í ¾à¹°Ä¡·á »Ó ¾Æ´Ï¶ó Á¤½ÅºÐ¼®Ä¡·á °°Àº È¿°úÀûÀÎ ½É¸®Ä¡·á¸¦ º´ÇàÇÏ¿© °¡´ÉÇÑ ºü¸¥ ½Ã°£³»¿¡ ȯÀÚÀÇ Ä¡·á¸¦ ¼º°øÀûÀ¸·Î Á¾°áÇÒ ¼ö ÀÖµµ·Ï ³ë·ÂÇÏ´Â ÆíÀÔ´Ï´Ù.
Á¤½ÅÁúȯ ¿ª½Ã ´Ù¸¥ ÀÇÇÐÀû Áúº´µéó·³ ¿À·¡ ¹æÄ¡µÉ¼ö·Ï ¾ÇȵǾî Àå±âÀûÀÎ ¿¹Èİ¡ ¾ÈÁÁ¾ÆÁö´Â °æ¿ì°¡ ´Ù¹Ý»çÀÔ´Ï´Ù. µû¶ó¼ Á¤½ÅÀûÀÎ ¹®Á¦°¡ ÀÖ´Ù°í ÀÎÁöÇÏ°Ô µÇ¸é °¡´ÉÇÑ »¡¸® °¡³¢¿î Á¤½Å°Ç°ÀÇÇаú Ŭ¸®´ÐÀ» ¹æ¹®ÇÏ¿© Áø·á¸¦ º¸°í Á¤È®ÇÑ Áø´Ü°ú Ä¡·á¸¦ ¹Ù·Î ½ÃÀÛÇϱ⸦ ±ÇÀ¯µå¸³´Ï´Ù.

À¯¹üÈñ Á¤½Å°Ç°ÀÇÇаú´Â 2014³â¿¡ °³¿øÇÏ¿´°í 3È£¼± µµ°î¿ª ±Ùó¿¡ À§Ä¡Çϰí ÀÖ½À´Ï´Ù. Á¤½Å°ú Àü¹®ÀÇÀÎ À¯¹üÈñ ¿øÀåÀ» Æ÷ÇÔÇÏ¿© ÀÓ»ó½É¸®Àü¹®°¡ 2Àΰú °£È£»ç 2¸íÀÌ ÇÔ²² ±Ù¹«Çϰí ÀÖ½À´Ï´Ù. ÁÖ·Î ºÒ¾ÈÀå¾Ö, °øÈ²Àå¾Ö, ¿ì¿ïÁõ, Á¶¿ïÁõ, ¼ö¸éÀå¾Ö, ¼ºÀÎ ADHD ȯÀÚµéÀ» Áø·áÇϰí ÀÖÀ¸¸ç ¾à¹°Ä¡·á »Ó ¾Æ´Ï¶ó °¢Á¾ ½É¸®Ä¡·á, Á¤½ÅºÐ¼®Ä¡·áµµ ÇÔ²² ½ÃÇàÇϰí ÀÖ½À´Ï´Ù.
¼¿ïƯº°½Ã °³²±¸ ¾ðÁÖ·Î 30±æ 21 ¾ÆÄ«µ¥¹Ì½ºÀ§Æ® Aµ¿ 202-3È£